<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03225235</url>
  </required_header>
  <id_info>
    <org_study_id>CYBERPROST</org_study_id>
    <nct_id>NCT03225235</nct_id>
  </id_info>
  <brief_title>Prospective Evaluation of Hypofractionated Stereotactic RT Using CyberKnife for Patients With Prostate Cancer</brief_title>
  <acronym>CYBERPROST</acronym>
  <official_title>Prospective Evaluation of Hypofractionated Stereotactic RT (SBRT) Using CyberKnife for Patients With Low and Intermediate Risk of Progression Prostate Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Greater Poland Cancer Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Greater Poland Cancer Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of study is to evaluate hypofractionated stereotactic radiotherapy (SBRT)
      using CyberKnife for Patients with low and intermediate risk of progression prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluation of the usefulness expression of selected proteins (PTEN, SMAD4, Cyclin D1, SPP1)
      as prognostic and predictive factors.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 26, 2013</start_date>
  <completion_date type="Anticipated">August 2025</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>survival time without biochemical recurrence,</measure>
    <time_frame>5 years</time_frame>
    <description>Phoenix definition of biochemical failure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>survival time specific for prostate cancer,</measure>
    <time_frame>5 years</time_frame>
    <description>the period of time from randomization until death from prostate cancer</description>
  </secondary_outcome>
  <other_outcome>
    <measure>QoL-EORTC quality of life</measure>
    <time_frame>5 years</time_frame>
    <description>For QoL the EORTC questionnaire (C30 with PR25) is used.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Hypofractionated Stereotactic SBRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>By assuming a hypofractionated irradiation scheme, it is assumed that between the fractions sublethal radiation damage is being treated and the time factor does not significantly affect RT result. The SBRT fractional dose was determined on the basis of a Biologically Effective Dose (BED) calculation using a linear-square model, which assumes that α / β takes the following values for:
tumor (RS) = 1.5
Late rectal and bladder complications = 3.0
early rectal and bladder complications = 10.0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SBRT</intervention_name>
    <description>hypofractionated stereotactic radiotherapy (SBRT) using CyberKnife for Patients With Low and Intermediate Risk of Progression Prostate Cancer</description>
    <arm_group_label>Hypofractionated Stereotactic SBRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  men from 40 to 75 years of age with a confirmed adenocarcinoma prostate, prostate
             biopsy will be performed &lt;180 days prior to the randomization date,

          -  completed assessment of tumor differentiation according to Gleason grading allows to
             perform stratification;

          -  general Performance Status according to the Eastern Cooperative Oncology Group (ECOG)
             classification ( 0 -1),

          -  belonging to the group of low and intermedium risk of progression; (cT1-cT2c, Gleason
             7, PSA to 19.9 ng / ml), cT specified by AJCC 7 Edition (appendix 2),

          -  PSA marked at least 10 days after or before the biopsy, and for patients taking
             phytosterol 30 days after discontinuation,

          -  no distant metastases,

          -  signing informed consent,

          -  morphological and biochemical blood parameters within the normal limits.

        Exclusion Criteria:

          -  the presence of active cancer, except skin cancer preceding period 5 years prior to
             randomization,

          -  surgical treatment (radical prostatectomy) or RT in the pelvic area,

          -  co-morbidities that may significantly affect the expectancy life of the patients

          -  do not meet the criteria for inclusion.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Piotr Milecki, PhD., MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Greater Poland Cancer Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Piotr Milecki, PhD., MD</last_name>
    <phone>+48618850878</phone>
    <email>piotr.milecki@wco.pl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sylwia Krąkowska, MD</last_name>
    <phone>+48 61 885 08 78</phone>
    <email>sylwia.krakowska@wco.pl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Greater Poland Cancer Centre</name>
      <address>
        <city>Poznan</city>
        <state>Wielkopolska</state>
        <zip>61-866</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piotr Milecki, MD PhD</last_name>
      <phone>+48 61 885 08 78</phone>
      <email>piotr.milecki@wco.pl</email>
    </contact>
    <contact_backup>
      <last_name>Sylwia Krąkowska, MA</last_name>
      <phone>+48 61 885 08 78</phone>
      <email>sylwia.krakowska@wco.pl</email>
    </contact_backup>
    <investigator>
      <last_name>Piotr Milecki, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2017</study_first_submitted>
  <study_first_submitted_qc>July 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2017</study_first_posted>
  <last_update_submitted>July 20, 2017</last_update_submitted>
  <last_update_submitted_qc>July 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate cancer, SBRT, Ultrafractionation, CyberKnife</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

